Google Answers Logo
View Question
Q: Research on the Pharmaceutical Industry ( Answered,   2 Comments )
Subject: Research on the Pharmaceutical Industry
Category: Miscellaneous
Asked by: gill53-ga
List Price: $50.00
Posted: 20 Jan 2003 09:18 PST
Expires: 19 Feb 2003 09:18 PST
Question ID: 145956
Hi there. I am looking for an overview of the pharmaceutical market,
the forces that are driving the sector example quest for manufacturing
excellence, lean manufacturing,regulatory compliance,generic
competition etc. The answer needs to include figures re growth rates
and if possible areas where pharma are spending money. Thank you!

Clarification of Question by gill53-ga on 20 Jan 2003 13:05 PST
$75 works for me.
Subject: Re: Research on the Pharmaceutical Industry
Answered By: pafalafa-ga on 20 Jan 2003 13:22 PST
Hello Gill53, and thanks for a challenging question.  As one commenter
noted, there's an awful lot of material to cover here (regardless of
the price!), but I think I can provide a reasonable overview.

The pharmaceutical industry is a huge, rapidly changing area of
commerce that is responding to a number of key market, regulatory and
technological forces.
A summary of the scope of the industry, and some of the driving forces
are as follows:

Size of the industry:  Global sales of pharmaceuticals amounted to
$392 billion dollars in 2001 (this applies chiefly to "prescription"
drugs, although different countries have different definitions at work
here).  This represents a growth of 12% over sales in 2000, and makes
the pharmaceutical industry one of the largest sectors of the global
economy.  The industry also seems less prone to economic gyrations
than, say, the automobile or housing industries, because, regardless
of economic conditions, people continue to get sick, and many outlays
for pharmacuticals are the result of government programs and/or
private insurance expenditures.  The U.S. is the largest consumer of
pharmacuticals, accounting for about 50% of the global market. Japan
is the second largest country market; Europe (as a whole) is also a
sizable consumer of pharmaceuticals.

Major Players:  Like many global industries, pharmaceuticals are
undergoing a period of intense restructuring and consolidation. 
Leading companies include Pfizer, Merck and Bristo-Meyers-Squibb in
the U.S.; GlaxoSmithKline and AstraZeneca in the U.K.; and Novartis
and Aventis in Europe.

Products:  Antiulcerants (heartburn medicines) are the leading area of
pharmaceutical products, headed by blockbuster products such as
Prilosec and Lipitor.  Other categories that are large and growing
particularly rapidly (20% or more per year)include:  cholesterol and
triglyceride reducers, antipsychotics, oral antidiabetics, and
systemic antihistamines.  Some other categories, although not as large
commercially, are also growing rapidly.  This is especially true for
HIV therapeuticals and erectile dysfunction drugs like Viagra.

Market Drivers:  Several forces are giving direction to the
pharmaceuticals market:

--Demographics:  The aging of the population, especially in the U.S.,
creates an expanding demand for drugs related to menopause, diabetes,
cholesterol, arthritis, and other conditions of old age.  Emerging and
epidemic diseases (HIV, flu epidemics, West Nile virus, "mad cow"
disease) create a need and/or public expectation of a successful
pharmaceutical treatment.

--Patents:  An explosion of pharmaceutical innovation in the past few
decades has created scores of new, successful drug products.  Many of
the patents on these products are due to expire in the foreseeable
future.  When the patent on Prozac expired, the drug's sales plummeted
by 70% in just two months, in favor of a generic substitute.
--Advertising:  The use of direct-to-consumer advertising for
pharmaceutical products -- unheard of not that long ago in the U.S. --
is credited by many observers as having spurred a good deal of the
rapid growth in global pharmaceutical sales.

Technological drivers: This industry is heavily invested in R&D,
spending an estimated $30 billion in 2001.  New avenues of research --
biotechnology (genetic engineering), genomic research (unlocking the
genetic code to understand and treat disease), pharmacogenetics
(targeting specific drugs to individuals depending on their genetic
structure) -- are opening up new areas of drug development. 
Sophisticated diagnostic and testing technologies are reducing the
time needed to screen and evaluate new chemicals as preliminary
candidates for a new drug. For instance, many screening tests that
formerly involved exposing laboratory animals for a period of months,
can now be carried on cell cultures much more rapidly.

Information technology has not only enabled more focused research
efforts, but has tied development more closely to market demands, as
manufacturers make use of real-time feedback from doctors and
pharmacies to gauge what conditions consumers (i.e. patients) are
seeking treatments for.

Regulatory situation:  Bringing a new drug to market can take decades,
partly due to the long research and development time, and partly due
to regulatory clearance procedures imposed by government agencies.  In
the U.S., the Food And Drug Administration has greatly speeded up new
drug reviews in recent years.  Observers are mixed as to the value
gained.  On the one hand, companies can bring new drugs to market much
faster, reducing costs and bringing benefits to consumers in need of
new medicines.  On the other hand, there have been reports of an
increasing number of adverse reactions to new drugs, causing some to
assume that drugs are entering the market without adequate safety


I hope this meets your needs for a brief yet thorough overview.  I try
to give the best answers possible, but if you feel additional
information is needed, please post a "Request for Clarification"
before rating this answer.

Pharma Overview
Current Industrial Reports

Numerous off-line printed reports

Request for Answer Clarification by gill53-ga on 21 Jan 2003 00:48 PST
Hi there. Thanks for that. Would you be able to point me in the right
direction so as I can do some further research on regulatory and lean
manufacturing drivers?

Clarification of Answer by pafalafa-ga on 21 Jan 2003 09:19 PST
I'll be happy to provide some additional information.  It will take a
bit of time, though.  I hope to have a response for you
tomorrow....stay tuned!

Clarification of Answer by pafalafa-ga on 21 Jan 2003 13:19 PST

Thanks for making your request so's a great help to me
in being able to follow up and meet your needs.  I'm going to suggest
here some general overview documents that are worth a look, along with
specific materials that address your request:

Overview of the pharmaceutical industry:

The annual report of the Pharmaceutical Research and Manufacturers of
America (PhRMA) is a must read.  It covers the basic economics of the
industry, recent advances, emerging trends in medicine and health
care, and regulatory and policy issues of importance to the industry,
both in the U.S. and around the world.

The PhRMA site has a number of other publications as well that are
worth exploring, especially the Pharmaceutical Industry Primer 2001:

and The PhRMA Industry Profile at:

Lean Manufacturing:

In my experience, the pharmaceutical industry is a bit more skittish
of lean manufacturing, six sigmas, and other "quality" trends than
most other manufacturing enterprises.  The reasons are twofold:

(1) the cost of manufacturing drugs is often only a small part of
overall industry costs, which can include huge outlays for R&D,
regulatory clearance, and marketing.  Profit margins in the
pharmaceutical are historically among the highest of any industry. 
Under these conditions, the economic incentive for trimming
manufacturing costs is not as keen as it might be in other sectors.

(2) drug manufacturers are traditionally loathe to tinker with a
production process that is working, fearing that *any* change to the
process – even one with the promise of significant cost savings –
might adversely impact the quality of the finished product.  If the
product is, say, paper towels, a temporary lapse in quality might be
worth the risk to achieve costs savings.  But when the product is a
medicine meant to save lives, a temporary lapse in quality could mean

Having said that, drug companies are certainly not immune to economic
pressure, and have adopted a great many techniques aimed at achieving
lean manufacturing operations, ranging from enterprise-wide
information approaches, to increasing precision in supply chain
management, to tinkering with the fundamental chemistry of the
drug-manufacturing process itself .  I've included a few links and
dead-tree articles to give you some background here:

Validation of Enterprise-Wide Systems: Lessons From the Field 
Enterprise resource planning in the pharmaceutical industry

Process Variability or Process Capability
Statistical process control in the pharmaceutical industry

Emerging Science Issues in Pharmaceutical Manufacturing: Process
Analytical Technologies
An exploration of recent advances in science that are changing the
nature of  pharmaceutical manufacturing.

An article in Chemical Week magazine, "Drug Industry Cost Pressure
Could Benefit Chemical Firms" (6/19/02) covers factors in the industry
that are leading an increasing number of companies to look more
aggressively for cost savings through lean manufacturing and other
quality improvement approaches.  (Chemical Week articles can be
accessed online if you subscribe to their site at [ ].

A subsequent Chemical Week issue (9/18/02) has a special multi-article
section that covers, in much more detail, innovations in the
pharmaceutical industry that are leading to greater process
efficiencies.  The articles have  intriguing titles like "Chiral
chemistry is an essential pharma kit component" and "Breakthrough
process development."  The issue covers some of the main efficiency
improvements being pursued in drug manufacturing.


I'm not sure what's more complicated: pharmaceutical chemistry or
pharmaceutical regulation.  One can easily devote a lifetime trying to
understand all the nuances at work here, but a few sites attempt to
make sense out of the regulatory morass, both in the U.S. and
elsewhere around the world:

Once again, PhRMA should be one of your first stops.  Their "Issues"
page at:

includes links and write-ups on Bioterrorism, Direct-to-Consumer
Advertising, FDA Issues, Genomics, lawsuits, Intellectual Property,
Medicaid, Medicare, Prescription Drug Costs, Reimportation, Research &
Development, Scientific and Regulatory Affairs.  All of these are "hot
button" areas that are regulated or potentially subject to regulation,
and are active (and complex) drivers in the industry.

Chemical and Engineering News magazine has some good overview articles
on regulatory issues, and I believe these are available to the public

Agency tries to find the right balance between thoroughness and
efficiency in drug approval

Long, Laborious Path To Drug Approval


Drug industry relies on those who navigate the ground between
development and approval

Lastly, a conference of a few years ago has put a number of its
presentations online, mostly in the form of Powerpoint slides.  But it
is worth a look:

The Second Annual Pharmaceutical Industry Regulatory & Compliance

I hope this is what you need, but if anything seems to be missing (or
if I've missed a target!), just let me know.

Clarification of Answer by pafalafa-ga on 21 Jan 2003 19:06 PST
Sorry...there were a few more links I inadvertently omitted:


Case Study: Medical/Pharmaceutical - Global Pharm Inc.[Enterprise
Resource Planning system implementation]

Accelerating Drug Development:  Regulatory Initiatives in the USA
Author: Murray M. Lumpkin, M.D. 
Deputy Center Director 
Center for Drug Evaluation & Research 
US Food and Drug Administration
State of the U.S. Drug Regulatory System

Clarification of Answer by pafalafa-ga on 18 Dec 2006 12:55 PST
I came across this list of biotechnology firms in the US, and thought
it would be of interest:

21st Century Biochemicals LLC
454 Life Sciences
ABBOTT Bioresearch Center (ABC)
Absolute Science, Inc.
Acambis, Inc.
Accelerated Cure Project for Multiple Sclerosis	
Acceleron Pharma, Inc.	
Accovion Inc.
ACOM* Healthcare
Addgene, Inc.
AdipoGenix, Inc.	
Advanced Cell Technology	
Advanced Magnetics, Inc.
AdvanDx, Inc.
Aeris Therapeutics, Inc.
Agencourt Bioscience Corporation
Alantos Pharmaceuticals, Inc.
Alexandria Real Estate Equities
Alnylam Pharmaceuticals
ALPCO Diagnostics	
ALS Therapy Development Foundation
ALTANA Research Institute
Altus Pharmaceuticals Inc.
Amaranth Bio Inc.
American Australian Association of New England	
American Integrated Biologics, Inc.
Amgen, Inc.
Ancora Pharmaceuticals, Inc.	
AniGenics Inc.
Anika Therapeutics, Inc.
Antigen Express, Inc.
Aphios Corporation
ApoConsult LLC	
Apple Computer, Inc.
Applied Risk Management, LLC
Archemix Corporation
Ardais Corporation
Ariad Pharmaceuticals, Inc.
Ariston Pharmaceuticals, Inc.
ArQule, Inc.
Arthur J. Gallagher & Company
Associates of Cape Cod, Inc.
AstraZeneca R&D Boston	
Athena Diagnostics, Inc.	
AVANT Immunotherapeutics, Inc.
Avatar Pharmaceutical Services, Inc.
Avecia Biotechnology, Inc.
AVEO Pharmaceuticals, Inc. (f/k/a GenPath Pharmaceuticals)
Averion, Inc.
Azopax Therapeutics
Babson Executive Education
BattelleCRO, Inc. (formerly CareStat
Beth Israel Deaconess Medical Center
BG Medicine, Inc.
Bingham McCutchen LLP
Bio-Concept Laboratories
Bioforce Solutions
Biogen Idec, Inc.
BioHelix Corporation	
Biomatic Technologies, Inc.
Biomeasure, Incorporated	
BioMed 20/20 Technologies, Inc.
Biomedical Research Models, Inc. (BRM)
Biometrix Corporation
Bionaut Pharmaceuticals
BioPhysics Assay Laboratory, Inc.
BioProcessors Corp.
Biopure Corporation
Bioscience Valuation LLC	
BioSquare at Boston University Medical Center
BioTeam Paris Region
BioTrove, Inc.
BioVentures Investors
BioVest International, Inc.
BioVex, Inc.
Blue Cross Blue Shield of Massachusetts
Blue Hive
Blue Sky Biotech, Inc.
Boston Analytical
Boston Biochem, Inc.
Boston Biomedical Research Institute
Boston Life Sciences, Inc.
Boston Properties
Bristol-Myers Squibb Medical Imaging
British Consulate -General
Bromberg & Sunstein, LLP
Caliper Life Sciences, Inc.
Cambrex Bioscience Hopkinton, Inc.
Cambria Biosciences LLC
Cambridge Biomedical Career Program
Cambridge Biomedical Research Group, Inc.
Canadian Consulate General
Capital Advisors Group
Capralogics, Inc.
Captains of Industry
Cardinal Health
Cardiovascular Clinical Studies, LLC
Cato Research - Boston
CB Richard Ellis Whittier Partners
CBR Institute for Biomedical Research
Celera Genomics
Cell Essentials, Inc
Cell NetwoRx LLC	
Cell Signaling Technology
Cellicon Biotechnologies Inc.	
CereMedix, Inc.
Cetek Corporation	
Charles River Laboratories
Chemic Laboratories, Inc.
Children's Hospital Boston, Intellectual Property Office
CIS - US, Inc.
Clarkston Consulting
CleanRooms Magazine	
Clinical Assistance Programs, LLC
Clinquest, Inc.
CNH Technologies, Inc.
Codexis, Inc.
Codon Devices	
Cohesive Technologies, Inc.
Coley Pharmaceutical Group
Collegium Pharmaceutical
CombinatoRx, Inc.
Comerica Bank/Technology & Life Sciences Division
Compound Therapeutics
CompuCyte Corporation
Comrise Technology, Inc.
conduit Systems, Inc.
Confluent Surgical, Inc.
Core2 Business Consulting, Inc.
Corning Incorporated
Correlagen, Inc.
Court Square Data Group
Covance Inc.
Craven & Ober, Policy Strategists, LLC
Critical Therapeutics, Inc.
Cubist Pharmaceuticals, Inc.
Curis, Inc.
Cyagra, Inc.
Cytel Inc.
Cytomatrix, LLC
Cytonome, Inc.
CytRx Laboratories, Inc. (formerly Araios)
Cytyc Corporation
D. Glass Associates, Inc.
Dacon Corporation
Daedalus Software, Inc.
Dana Farber Cancer Institute
Decision Biomarkers
Deloitte & Touche LLP
DePuy Biologics	
Domantis, Ltd.
Dow Biopharmaceutical Contract and Manufacturing Services
Drug Development Resources, Inc.
Duane Morris LLP	
Dyax Corporation
Dynogen Pharmaceuticals
Edwards Angell Palmer & Dodge LLP
Eisai Research Institute of Boston, Inc.
Elixir Pharmaceuticals, Inc.
Elucida Research LLC	
EMD Lexigen Research Center Corp.
ENANTA Pharmaceuticals, Inc.
Endpoint Research LLC
Ensemble Discovery Corporation
Envirotainer, Inc.
EnVivo Pharmaceuticals, Inc.
Epic Therapeutics, Inc.	
Epitome Biosystems
EpiVax Inc.
EPIX Pharmaceuticals, Inc.
Equis Corporation
Ernst & Young
ETEX Corporation
Exact Sciences Corporation
Exalpha Biologicals, Inc
Expressive Constructs Inc.
Eyetech Pharmaceuticals, Inc.
Feinstein Kean Healthcare
Fidelity Bioscience Group	
Finnegan, Henderson, Farabow, Garrett & Dunner, LLP
Fish & Richardson P.C.
Fisher Scientific International
Flagship Ventures	
Fleishman - Hillard	
FoldRx Pharmaceuticals
Foley & Lardner LLP
Foley Hoag LLP
Forest City Commercial GroupBoston Forest City Science + Technology
Formatech, Inc.
Foster Design Group, Inc.
Fox Relocation Management Corp.
French Office for Science and Technology	
Fresenius Biotech North America, Inc.	 http://
Fulcrum Pharma Development Inc.
Fusion Medical Education, LLC
Gene Logic Inc.
Genetic Services, Inc.
Genetix Pharmaceuticals, Inc.
Genfit Corp.
Genitrix, LLC
Genomic Profiling Systems, Inc.
Genomics Collaborative
Genstruct, Inc.
GenVec, Inc.
Genzyme Corporation
GlaxoSmithKline, Inc.
Global Prior Art, Inc.
Gloucester Pharmaceuticals
GLSynthesis, Inc.
GlycoFi, Inc.
GlycoGenesys, Inc.
Goodwin Procter LLP
GPC Biotech Inc.
Green Mountain Antibodies
GTC Biotherapeutics, Inc.
Gwathmey Inc.
Hammond Hill LLC
Harvard Clinical Research Institute (HCRI)
Harvard Extension School
Harvard Medical School
Health Advances, Inc.
Helicos BioSciences Corporation
HireMinds LLC
Histogenics Corporation
Hudson Scientific
Hyaluron, Inc.
Hydra Biosciences
Hypnion, Inc.
IBM Corporation
ID Biomedical
Idenix Pharmaceuticals, Inc.
Idera Pharmaceuticals
Immerge BioTherapeutics, Inc.
Immunetics, Inc.
ImmunoGen, Inc.
IMPACT Technology Consultants
Indevus Pharmaceuticals, Inc.
Indiana Centers for Applied Protein Sciences (INCAPS)
Indigene Pharmaceuticals, Inc.
Infinity Pharmaceuticals, Inc.
Innovation Norway	
Inotek Pharmaceuticals Corporation
Intelligent Medical Devices, Inc.
Intercytex Ltd.
Interleukin Genetics, Inc.
International Biotechnology Investment Corp.	
Invest Northern Ireland
Invitrogen Corporation
IQuum, Inc.
J. Calnan & Associates Inc.	
JETRO (Japan External Trade Organization)
Johnson Matthey Pharma Services
Kard Scientific
Keel Pharmaceuticals	
Keystone Partners
Kforce Scientific and Clinical Research Group
Kirkpatrick & Lockhart Nicholson Graham LLP
L.E.K. Consulting LLC
LabPros, Inc.
LaVoie Strategic Communications Group, Inc.
LCT Biopharma, Inc.
Levin & Company
Lex Company	
Life Science Insights
Link Medicine Corporation	
LNR Property Corporation
Lonza Biologics, Inc.
Lyme Properties, LLC
M Squared Consulting Inc.
Mabbett & Associates Inc.	
MacDougall Biomedical Communications, Inc.
MacroChem Corporation
MannKind BioPharmaceuticals
Marinus Pharmaceuticals, Inc.
Marsh Inc.
Massachusetts Biomedical Initiatives (MBI)
Massachusetts College of Pharmacy & Health Sciences
Massachusetts Institute of Technology	 http://
Massachusetts Office of International Trade and Investment, State
Transportation Building
Matritech Inc.
Maxiom Consulting Group	 http://www.MaxiomGroup.Com
MaxThera Inc.	
MBL International
McDermott Will & Emery LLP
MedImmune Inc.	
MedPanel, Inc
MedSafe, Inc.
Merck & Co., Inc.
Mercury Computer Systems
Mercury Therapeutics, Inc.	
Meredith & Grew Inc.	
Merrimack Pharmaceuticals, Inc.
Mersana Therapeutics	
Metabolix, Inc.
MetriGenix Corporation
MGI Pharma Biologics, Inc.
Microbia, Inc.
Microbiotix, Inc.
MicroCHIPS, Inc.
MicroTest Laboratories (MTL), Inc.
Millennium Pharmaceuticals, Inc.
Millipore Corporation
Minerva Biotechnologies Corp.	
Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.	
Modular Genetics, Inc.
Molecular Insight Pharmaceuticals, Inc.
Momenta Pharmaceuticals, Inc.
Mouse Specifics, Inc.
MPM Capital
NAI Hunneman Commercial Co.
Nanobiosym Inc.	
Nantero, Inc.
Needham & Co., Inc.
Neurogen Corp.
Neurotech USA, Inc.
New England Healthcare Institute
New England Peptide, Inc.
New England Testing Laboratory, Inc.
New World Laboratories	 http://www.NewWorldLabs.Com
NitroMed, Inc.
Nixon Peabody LLP
Northeastern University
Novartis Institutes for BioMedical Research, Inc.
NovoBiotic Pharmaceuticals
Nuclea Biomarkers LLC	
NUCRYST Pharmaceuticals Corp.
Nutter McClennen & Fish, LLP
OmniGene Bioproducts, Inc.
Oncogene Science Diagnostics
One Cell Systems, Inc.
Organogenesis, Inc.
Organon Research Center USA
Oscient Pharmaceuticals
Osmetech, Inc.
Oxford Bioscience Partners
Oxford Finance Corporation
Oxxon Therapeutics Inc.
P. P. Manufacturing Corporation	 
P.A. Technologies	
PA Consulting Group
Panacea Clinical Research
Parallel Solutions, Inc.
Paratek Pharmaceuticals, Inc.
PAREXEL International Corp.
Partners Healthcare System, Inc.
Peptimmune, Inc.
Pervasis Therapeutics, Inc.
Pfizer, Inc.- Research Technology Center
Pharma Bio-Research USA Inc.
PharmaMar USA Inc.
PharmaPros Corporation
Phase Forward, Inc.
Phasex Corporation	
PHT Corporation	
Phylogix, Inc.
Phylonix Pharmaceuticals, Inc.
Pixel Bridge Inc.
Point Therapeutics Inc.
Polaris Venture Partners
PolyOrg, Inc.
PPD, Inc.
PRAECIS Pharmaceuticals, Inc.
Predix Pharmaceuticals, Inc.
Pressure BioSciences, Inc.
Prestige Executive Search Corporation
PricewaterhouseCoopers LLP
Primera Biosystems	
Produce Safety Solutions, Inc.
Pro-Motions, Inc.
Pro-Pharmaceuticals, Inc.
Protein Forest, Inc.
Proteome Systems
Quebec Delegation
Queensland, Australia Trade & Investment Office
QuickSTAT - A division of Quick International Courier
Quintiles Transnational Corp.
Radius (formerly Nuvios)
Randstad (old)
RDW Group Inc.	
Regis College
RenaMed Biologics	
Repligen Corporation
RiboNovix, Inc.
Rib-X Pharmaceutical, Inc.
Ricerca Biosciences LLC	
Ropes & Gray
Ross Systems
Sanofi Aventis Pharmaceuticals
Saoirse Corporation
SBH Sciences, Inc.
SBR Pharmaceuticals Corp.	
Scimitar Equity Research, Inc.
Scion Pharmaceuticals, Inc.
Scottish Development International
Seahorse Bioscience
Securitas - Pinkerton Consulting & Investigations
SelectX Pharmaceuticals, Inc.
SemanTx Life Sciences Inc.	
Sepracor Inc.
Serono, Inc.
Shire Pharmaceuticals
Signet Laboratories, Inc.
Silicon Valley Bank
Sirtris Pharmaceuticals
Spanish Biotechnology Association	 http://www.SpanishBiotech.Org
Spaulding & Slye
Spherics, Inc.
State Street Bank & Trust Co., High Technology Group
Stryker Biotech
Suffolk University	
Sullivan Insurance Group
Surface Logix, Inc.
Synta Pharmaceuticals Corp.
Syntonix Pharmaceuticals, Inc.
Talent Capital Group
Techmark Security Integration Inc
Techno Venture Management
Technology Management Corporation
TEI Biosciences, Inc.
Tepha, Inc
Tepnel LifeCodes Corporation
Teranode Corporation	
Tessella Inc.
TGA Sciences, Inc.
The Brigham and Women's Hospital
The Forsyth Institute
The Frankel Group, Inc.
The GI Company
The Jackson Laboratory	
The Richmond Group, Inc.
Therion Biologics Corp.
Thermo Electron Corporation
Thrasos Therapeutics	
Tissue Regeneration, Inc.
TolerRx Inc.
Total ReCord Inc.	
Toxikon Corporation
Trammell Crow Company
TransForm Pharmaceuticals, Inc.
TransMolecular Inc.	
Transport Pharmaceuticals	
Trine Pharmaceuticals, Inc.
Tufts University
Turner Construction Company
U.S. Genomics, Inc.
Unither Pharmaceuticals, Inc.
University of Connecticut Technology Incubation Program	
University of Massachusetts
University of Massachusetts Medical Center Office of Technology
Vaccine Technologies, Inc.	
Verax Biomedical Incorporated
Versal Technologies, Inc.
Vertex Pharmaceuticals Inc.
ViaCell, Inc.
Vienna Business Agency
VisEn Medical
Waterview Information Technology
Whitehead Institute
William Gallagher Associates
Wilmer Cutler Pickering Hale and Dorr LLP
Wolf Greenfield & Sacks
Wolfe Laboratories, Inc.
Worcester Polytechnic Institute
WorldCare Clinical Trials, Inc.
Wyeth Pharmaceuticals and Research Headquarters
Xanthus Life Sciences, Inc.
Xcellerex, Inc.
Xemplar Pharmaceuticals, LLC
Zapaq, Inc.	
Zelos Therapeutics
ZymeQuest, Inc.
Subject: Re: Research on the Pharmaceutical Industry
From: jbf777-ga on 20 Jan 2003 12:19 PST
Hi -

You may want to consider upping the price point of your question to
the $75+ range due to the breadth of what you're requiring.

GA Researcher
Subject: Re: Research on the Pharmaceutical Industry
From: tom136-ga on 22 Apr 2003 10:13 PDT
You can check: --> worldwide pharma market 2000

Do not forget to visit: (a very well-known
provider of medicines sales data). Some general snapshots are free.
You also can buy selected reports from open IMSHealth.

Check also this link:

An intersting link from Bioscorpio:
Click on the different medical conditions/diseases/therapeutic areas
in the left column in order to get a brief snapshot of the US market
related to that condition/therapeutic area.


Important Disclaimer: Answers and comments provided on Google Answers are general information, and are not intended to substitute for informed professional medical, psychiatric, psychological, tax, legal, investment, accounting, or other professional advice. Google does not endorse, and expressly disclaims liability for any product, manufacturer, distributor, service or service provider mentioned or any opinion expressed in answers or comments. Please read carefully the Google Answers Terms of Service.

If you feel that you have found inappropriate content, please let us know by emailing us at with the question ID listed above. Thank you.
Search Google Answers for
Google Answers  

Google Home - Answers FAQ - Terms of Service - Privacy Policy